US appeals court upholds West Virginia restriction on abortion pill sales
A three-judge panel of the 4th U.S. Circuit Court of Appeals in Richmond, Virginia, affirmed a ruling by a U.S. district judge in 2023 despite federal regulators' approval of the abortion pill as a safe and effective medication.
Most Republican-controlled states have enacted or adopted abortion bans of some kind, including restricting abortion pills by default, since the U.S. Supreme Court in 2022 overturned Roe v. Wade, the 1973 ruling that provided nationwide access to abortion. All have been challenged in court. The Supreme Court ruled in the case of Dobbs v. Jackson Women's Health Organization.
U.S. District Court Judge Robert C. Chambers had ruled that the near-total abortion ban signed by then-Republican Gov. Jim Justice in September 2022 took precedence over approvals from the U.S. Food and Drug Administration.
"For us to once again federalize the issue of abortion without a clear directive from Congress, right on the heels of Dobbs, would leave us one small step short of defiance," 4th Circuit Judge J. Harvie Wilkinson III wrote for the court.
'One can of course agree or disagree with the Dobbs decision. But that is not the point,' Wilkinson said. 'At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option.'
West Virginia Gov. Patrick Morrisey, who took office in January, had defended challenges to the abortion law when he served as attorney general.
"Big win out of the 4th Circuit today,' Morrisey said in a statement.
GenBioPro Inc., the country's only manufacturer of a generic version of the abortion pill mifepristone, had argued that the state cannot block access to a FDA-approved drug. Chambers had dismissed the majority of GenBioPro's challenges, finding there is 'no disputing that health, medicine, and medical licensure are traditional areas of state authority.'
Appeals judge DeAndrea Gist Benjamin concurred and dissented in part Tuesday, calling it a 'troubling opinion.'
'Put plainly, this law erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress,' Benjamin wrote.
Not at issue in the appeal was a challenge by GenBioPro concerning a separate West Virginia law that stopped providers from prescribing mifepristone by telehealth. Chambers had allowed that challenge to proceed. The U.S. Supreme Court last year unanimously preserved access to mifepristone, which is used in nearly two-thirds of all abortions in the U.S. in 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
16 minutes ago
- Boston Globe
Texas just opened Pandora's box, and voters everywhere could pay the price
Redistricting is meant to occur every 10 years after the census. District maps should ensure that all voters have an equal chance to influence their representation, not to serve the personal or political interests of those in power at a given moment. Advertisement What makes this instance particularly troubling is the brazen nature of the effort. Trump and Republican leaders in Texas have been blunt: This new map is designed purely for Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up But this is not just a Texas problem. The consequences are already rippling outward: Lawmakers in New York and California are now considering redrawing their own maps in response — not to better serve communities but to counterbalance Texas's partisan moves. This tit-for-tat escalation is exactly what our democratic system cannot afford. Partisan gerrymandering has always been problematic, but Texas's mid-decade redistricting solely for political advantage is particularly corrosive to our democracy. Political leaders in Washington, D.C., have been gutting health care, tearing apart families with abusive deportation squads, and using federal power for revenge and personal gain. Rather than earning electoral victories by engaging with their constituents and championing policies that improve people's lives, they have chosen to simply redraw the district boundaries. As state Representative Advertisement This power grab is particularly harmful in Texas, a state with a long history of racially discriminatory map drawing and other forms of voter suppression. In Americans deserve better. We deserve fair maps designed to reflect communities, not to boost the political fortunes of the map drawers. And no matter which party is in power, partisan gerrymandering cannot come at the expense of voters of color and diluting their vote and voice. We the voters should choose our elected officials — not the other way around. This moment demands national urgency. Mid-decade gerrymandering to avoid answering to voters is already dangerous. Now the governor and attorney general of Texas are Advertisement Texas's actions set a dangerous precedent. If the nation's second largest state can conduct partisan redistricting mid-decade with impunity, other states will follow suit. We're witnessing a race to the bottom that erodes faith in democratic institutions, regardless of which party benefits. We the people are supposed to command our own fate. That means our representatives are supposed to work for us. Texas must back away from mid-decade redistricting. And Congress must act to end partisan gerrymandering and protect the freedom to vote for all Americans, especially those most targeted by these power grabs. Texas is showing us what happens when those in power use that power to entrench themselves instead of serving their constituents. If Texas gets away with this, this mid-decade power grab won't be an aberration — it will drag other states into the same game, and voters and our democracy will be the losers.
Business Upturn
21 minutes ago
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
New York Post
2 hours ago
- New York Post
William H. Webster, only person to lead both FBI and CIA, dies at 101
William H. Webster, the former FBI and CIA director, has died at the age of 101, his family announced Friday. Webster led the FBI from 1978 to 1987 and the CIA from 1987 to 1991, making him the only person to head the nation's top law enforcement agency and its main intelligence agency. 'We are proud of the extraordinary man we had in our lives who spent a lifetime fighting to protect his country and its precious rule of law,' his family said in a statement. Before his time leading agencies in Washington, he served as a federal prosecutor and later spent about eight years as a federal judge. He also served in the US Navy during World War II and the Korean War. Former President Jimmy Carter tapped Webster, a Republican, for a 10-year term as head of the FBI as the agency attempted to boost a reputation that had been tarnished by revelations of domestic spying, internal corruption and other abuses of power. William H. Webster has died at the age of 101. AP Webster was later selected by President Ronald Reagan to lead the CIA, replacing director William J. Casey, who had been criticized for being too political, ignoring Congress and contributing to the arms-for-hostages scandal known as Iran-Contra. 'Every director of the CIA or the FBI should be prepared to resign in the event that he is asked to do something that he knows is wrong,' Webster once said. In 2002, the Securities and Exchange Commission chose Webster to lead a board created by Congress to oversee the accounting profession in response to scandals involving Enron and other corporations. The FBI said it sends its prayers and condolences to Webster's family after learning of his passing. Webster was congratulated by President Jimmy Carter after being sworn in as new director of the FBI in Washington, Feb. 23, 1978. AP 'He was a dedicated public servant who spent over 60 years in service to our country, including in the US Navy, as a federal judge, director of the CIA, and his term as our Director from 1978-1987,' the agency said in a statement. 'We are grateful for his life and legacy and wish his family, friends, and colleagues peace and comfort during this time.' Former FBI Director Christopher Wray, who departed the agency earlier this year, said he was 'deeply saddened' by Webster's death. 'My heart goes out to his family in this time of loss. His legacy will endure — not only in the institutions he guided, but in the generations of public servants he inspired to carry the torch forward,' Wray said in a statement. Webster is survived by his second wife, Lynda Clugston Webster, and three children from his first marriage and their spouses, seven grandchildren and spouses and 12 great-grandchildren. His first wife, Drusilla Lane, died in the 1980s.
